← Back to All Filings

Viatris Director Acquires 26k Shares via RSU Vesting

Low SignificanceMarch 10, 2026 at 7:18:05 PM EDT

Viatris Inc

$VTRS4CIK: 0001792044

Subscribe to track VTRS

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Viatris Director Acquires 26k Shares via RSU Vesting

Company: Viatris Inc (VTRS) Form: 4 | Filed: 2026/03/10 Significance: Low

Insider: DAMELIO FRANK A Title: Director | Relationship: Director

Transaction: • Type: Grant/Vest • Shares: 26,031 • Price: $0.00 • Value: $0.00 • Owned After: 26,031

Key Insight: Routine vesting of Restricted Stock Units (RSUs) and Dividend Equivalents; no open market activity.

Market Context: Transaction represents negligible dilution (0.002% of outstanding shares) for this $17.19B market cap company.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: Viatris Inc (VTRS)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Routine vesting of equity compensation and new annual grant; no open market signaling.
  • Market Impact: Neutral - transaction is administrative in nature.

Company Information

FieldValue
CompanyViatris Inc
Ticker SymbolVTRS
CIK0001792044
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameDAMELIO FRANK A
CIK0001194004
Title/PositionDirector
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2026-03-06
Transaction CodeM (Exercise/Conversion)
Security TypeCommon Stock
Shares Involved26,031
Price Per Share$0.00
Total Value$0.00
Shares Owned After26,031
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0 (Vesting)
% of Market Cap0.00%
Shares Transacted26,031
% of Shares Outstanding0.002%
Post-Transaction Ownership26,031 shares (0.002% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: Viatris is a Large Cap company ($17.19B). This transaction is microscopic relative to the company's size.
  • Ownership Concentration: The insider holds a very small fraction of the 1.15 billion shares outstanding.
  • Dilution Impact: The vesting of 26,031 shares and new grant of 15,890 RSUs creates negligible dilution (<0.01%).
  • Transaction Significance: The transaction involves the settlement of RSUs and Dividend Equivalent Units (DEUs) for $0, which is standard compensation procedure and does not reflect market sentiment.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This is a non-discretionary transaction related to compensation plans. It provides no information regarding the insider's view of the stock's future performance.

Volume & Sentiment

  • Expected Volume Impact: None.
  • Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

  • Details: The reporting person acquired 25,112 shares via RSU vesting and 919 shares via Dividend Equivalent Units.
  • New Grants: The filing also discloses a new grant of 15,890 RSUs vesting in March 2027.
  • Timing: Annual vesting cycle (March).
Topics:#VTRS#Viatris#SECFiling#Form4#InsiderTrading#StockMarket#Pharma#FinancialEducation

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.